Zanidatamab binds HER2 on tumor cells and its Fc region recruits immune effectors, inducing ADCC (NK cells), ADCP (macrophages), and CDC (complement), leading to killing of HER2-expressing cells; it also blocks HER2 signaling and promotes internalization/downregulation.